Insider Trading March 30, 2026

Lemonade Director Increases Stake with $485k in Stock Purchases

Maria Angelidis-Smith adds to direct and trust holdings as company posts stronger-than-expected Q4 2025 results

By Jordan Park LMND
Lemonade Director Increases Stake with $485k in Stock Purchases
LMND

Lemonade, Inc. director Maria Angelidis-Smith purchased a total of $485,478 in common stock on March 10, 2026, split between direct and trust transactions. The moves were disclosed in a Form 4/A filing with the Securities and Exchange Commission. The company recently reported fourth-quarter 2025 results that beat analyst expectations on both earnings per share and revenue, prompting mixed analyst reactions.

Key Points

  • Director Maria Angelidis-Smith purchased a total of $485,478 in Lemonade common stock on March 10, 2026, split between direct and trust transactions.
  • Following the trades, Angelidis-Smith directly owns 14,896 shares and indirectly owns 38,944 shares via the Smith Family Trust.
  • Lemonade beat Q4 2025 expectations with EPS of -$0.29 and revenue of $228 million, prompting mixed analyst reactions including a price-target raise by Keefe, Bruyette & Woods and an upgrade from Morgan Stanley.

Summary: Lemonade, Inc. (NYSE:LMND) director Maria Angelidis-Smith acquired shares in the company on March 10, 2026, in two separate transactions totaling $485,478, according to a Form 4/A filed with the Securities and Exchange Commission. The purchases were executed at prices between $55.30 and $55.70 per share. The stock has appreciated 87% over the past year and is trading at $61.11 with pronounced volatility, per InvestingPro analysis.


Insider purchase details: The filing shows Angelidis-Smith bought 3,350 shares directly at $55.30 per share. In addition, 5,390 shares were acquired indirectly through the Smith Family Trust, of which Angelidis-Smith serves as a Co-Trustee, at $55.70 per share. After these transactions, her direct ownership stands at 14,896 shares and her indirect holdings through the Smith Family Trust total 38,944 shares.

The aggregate dollar value of the two transactions equals $485,478. The reported price range for the purchases was $55.3 to $55.7. InvestingPro analysis notes that LMND has returned 87% over the previous 12 months and is currently quoted at $61.11, while exhibiting high volatility.


Recent company performance and analyst reactions: Lemonade reported fourth-quarter 2025 results that exceeded analyst expectations on both the bottom line and revenue. The company posted earnings per share of -$0.29, ahead of the -$0.39 consensus, and reported revenue of $228 million versus an expected $216.26 million, representing a 5.43% revenue surprise.

Following the earnings release, Keefe, Bruyette & Woods increased its price target for Lemonade to $44 from $40 but retained an Underperform rating, citing stronger premium growth and lower loss ratios as factors. Separately, Morgan Stanley upgraded Lemonade from Equalweight to Overweight, pointing to the strategic potential of Lemonade's partnership with Tesla in the auto insurance market and describing the arrangement as providing a first-mover advantage in data analysis and operational experience.


Other corporate governance developments: In related reporting, Riskified announced that Dr. Samer Haj-Yehia will join its board of directors effective March 19, following the resignation of Aaron Mankovski. The announcement says Dr. Haj-Yehia brings extensive experience in financial services and fintech to the board.

Access to further analysis: For investors seeking deeper valuation work and a more detailed breakdown of Lemonade's financials and outlook, a Pro Research Report is available on InvestingPro.


What this record shows: The Form 4/A disclosure provides a transparent record of the director's purchase activity and the resulting shareholdings. The company’s recent quarterly results and subsequent analyst responses are included in public filings and market commentary cited above.

Risks

  • The stock is described as highly volatile, which can increase short-term price swings and investment risk for shareholders in the technology and insurance sectors.
  • Analyst sentiment remains mixed despite the earnings beat: Keefe, Bruyette & Woods maintained an Underperform rating even after raising its price target, indicating lingering concerns in equity markets for the company.
  • Insider purchases do not eliminate company-specific operational or market risks tied to Lemonade’s business model and competitive positioning in the insurance and insurtech sectors.

More from Insider Trading

GlobalFoundries’ CLO Disposes of $22,995 in Stock as Company Faces Legal and Capital Moves Mar 30, 2026 Neuronetics Insider Adds $675,000 in Shares as Company Reports Mixed Q4 Results Mar 30, 2026 Horace Mann CMO Makes Modest Stock Purchase as Company Posts Strong Q4 Results Mar 30, 2026 IperionX President Purchases $262,552 in ADS as Coverage Begins and Production Ramps Mar 30, 2026 LightPath CEO Makes Small Personal Purchase as Company Posts Revenue Beat but EPS Misses Mar 30, 2026